Browse studies

Find your next paid study

4 recruiting studies matching your filters

Newest first Highest paying

Phase 1

A Phase 1, Open Label, Dose Response, Pilot Study to Evaluate the Safety and Tolerability of Human Fibroblast Growth Factor-1 (FGF-1) in Peripheral Arterial Disease Patients With Intermittent Claudication

FGF-1 for the treatment of patients with peripheral arterial disease with intermittent claudication.

Peripheral Arterial DiseaseStenosisIntermittent Claudication

Estimated

~$10 – $8,750

Venturis Therapeutics, Inc.NCT00424866

Phase 2

Response to Exercise and Nitric Oxide in Peripheral Artery Disease: The RESIST PAD Trial

RESIST PAD is a randomized trial of 200 PAD patients to establish: 1) whether a 12-week exercise intervention significantly increases Δ nitrite at 12-week foll…

Peripheral Artery DiseaseExerciseIntermittent Claudication+1 more

Estimated

~$10 – $6,250

Northwestern UniversityNCT06657976

Phase 3

IMProving Mobility After revasCularizaTion in Peripheral Artery Disease: The IMPACT PAD Trial

Lower extremity revascularization combined with supervised exercise significantly improves walking performance compared to revascularization alone in people wh…

Peripheral Artery DiseaseIntermittent ClaudicationPeripheral Vascular Disease+2 more

Estimated

~$10 – $6,250

Northwestern UniversityNCT06686121

Phase 3

Metformin BenefIts Lower Extremities With Intermittent Claudication (MOBILE_IC)

Peripheral arterial disease (PAD) affects over 20% of aged adults and is very common among Veterans due significant tobacco use. PAD is due to the progressive …

Intermittent Claudication

Estimated

~$10 – $5,625

VA Office of Research and DevelopmentNCT05132439